Search Results - "Zuo, Bangyou"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
  2. 2

    Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma by Sun, Huishan, Long, Junyu, Zuo, Bangyou, Li, Yiran, Song, Yu, Yu, Minghang, Xun, Ziyu, Wang, Yanyu, Wang, Xi, Sang, Xinting, Zhao, Haitao

    Published in BMC cancer (18-05-2023)
    “…Selenium metabolism has been implicated in human health. This study aimed to identify a selenium metabolism regulator-based prognostic signature for…”
    Get full text
    Journal Article
  3. 3

    Real-time indocyanine green fluorescence imaging and navigation for cone unit laparoscopic hepatic resection of intrahepatic duct stone: a case series study by Hao, Jianjie, Cheng, Donghui, Jiang, Jipeng, Zuo, Bangyou, Zhang, Yu

    “…Intrahepatic bile duct stones, although common and benign, require varying therapeutic strategies due to their recurrent nature. Inadequate management can…”
    Get full text
    Journal Article
  4. 4

    Liver resection with two-step vascular exclusion, in situ hypothermic portal perfusion for the treatment of end-stage hepatic alveolar echinococcosis by You, Xinyu, Zuo, Bangyou, Jiang, Jipeng, Cheng, Donghui, Li, Peng, Xing, Hongming, Yang, Chong, Zhang, Yu

    Published in Langenbeck's archives of surgery (30-05-2024)
    “…Purpose To evaluate the safety and efficacy of two-step vascular exclusion and in situ hypothermic portal perfusion in patients with end-stage hepatic…”
    Get full text
    Journal Article
  5. 5

    A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer by Zuo, Bangyou, Yang, Xiaobo, Yang, Xu, Bian, Jin, Long, Junyu, Wang, Dongxu, Ning, Cong, Wang, Yanyu, Xun, Ziyu, Wang, Yunchao, Lu, Xin, Mao, Yilei, Sang, Xinting, Zhao, Haitao

    Published in Cancer Immunology, Immunotherapy (01-08-2022)
    “…Background Anti-PD-1 antibodies plus lenvatinib therapeutic regimens have demonstrated a relatively high antitumor response in many solid cancers; however, the…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma by Pang, Beichuan, Zuo, Bangyou, Huang, Liang, You, Xinyu, Liu, Tao, Hao, Jianjie, Yuan, Chengxiang, Yang, Chong, Yee Lau, Wan, Zhang, Yu

    Published in International immunopharmacology (20-08-2024)
    “…•Efficacy and safety of TACE and HAIC combined with TKIs and PD-1 inhibitors in unresectable hepatocellular carcinoma (uHCC) were evaluated.•Key findings:…”
    Get full text
    Journal Article
  8. 8

    The efficacy and safety of single-incision plus one-port laparoscopic surgery vs. conventional five-port laparoscopic surgery for duodenum-preserving pancreatic head resection by Zuo, Bangyou, You, Xinyu, Jiang, Jipeng, Cheng, Donghui, Li, Peng, Yang, Chong, Zhang, Yu

    Published in Gland surgery (31-08-2024)
    “…Single-incision plus one-port laparoscopic duodenum-preserving pancreatic head resection (SILDPPHR+1) is yet to be reported, and therefore, its safety and…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinoma by Zuo, Bangyou, Kuai, Jing, Long, Junyu, Bian, Jin, Yang, Xu, Yang, Xiaobo, Xun, Ziyu, Li, Yiran, Sun, Huishan, Sang, Xinting, Zhao, Haitao

    Published in Annals of translational medicine (01-08-2022)
    “…BackgroundExosomes are involved in cell-to-cell communication, neovascularization, cancer metastasis, and drug resistance, which all play an important role in…”
    Get full text
    Journal Article
  11. 11

    CMTTdb: the cancer molecular targeted therapy database by Bai, Xue, Yang, Xiaobo, Wu, Liangcai, Zuo, Bangyou, Lin, Jianzhen, Wang, Shanshan, Bian, Jin, Sang, Xinting, He, Yungang, Yang, Zhen, Zhao, Haitao

    Published in Annals of translational medicine (01-11-2019)
    “…The cancer molecular targeted therapy has achieved unprecedented progress in the past decade and is thought to be the most promising direction for cancer…”
    Get full text
    Journal Article